Sigilon Therapeutics, Inc.

Sigilon Therapeutics, Inc. is a clinical stage biotechnology company focused on developing functional cures for chronic diseases. Its lead product candidate, SIG-001, is in Phase I/II clinical trial for Hemophilia A. The company is also developing SIG-005 for mucopolysaccharidosis type 1, SIG-007 for Fabry disease, and SIG-002 for type 1 diabetes. Sigilon has a research collaboration and license agreement with Eli Lilly and Company for the development and commercialization of SLTx product candidates for type 1 diabetes treatment.

Products

• SIG-001 for Hemophilia A

• SIG-005 for mucopolysaccharidosis type 1

• SIG-007 for Fabry disease

• SIG-002 for type 1 diabetes